Analyst Roger Song of Jefferies maintained a Buy rating on Disc Medicine (IRON – Research Report), with a price target of $111.00.
Roger Song’s rating is based on Disc Medicine’s strategic progress and promising market potential. The company is advancing towards key regulatory milestones, including the submission of an NDA for their lead candidate, Bito, in treating EPP by the second half of 2025. This progress is supported by a strong clinical data package from previous trials and ongoing studies, which bolsters confidence in their regulatory pathway.
Additionally, Disc Medicine is targeting a significant market opportunity with their innovative treatments. The addressable market for EPP in the U.S. is estimated to be between 6,000 to 14,000 patients, with potential for expansion. Moreover, their development of DISC-0974 for anemia in myelofibrosis and chronic kidney disease presents further growth prospects, as these areas have unmet medical needs. The company’s engagement with both the FDA and EMA for potential approvals in the U.S. and EU markets further strengthens their commercial outlook.
In another report released on March 6, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $85.00 price target.
IRON’s price has also changed slightly for the past six months – from $47.790 to $52.410, which is a 9.67% increase.